Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases with high unmet medical needs [2][3] - The company's lead programs include losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD) and other hemoglobinopathies [2][3] Upcoming Presentations - Fulcrum Therapeutics announced upcoming presentations at the 31st Annual FSHD Society International Research Congress on June 13-14, 2024, in Denver, Colorado [3] - Presentations will include an abstract on the baseline characteristics of patients in the Phase 3 REACH trial of losmapimod in FSHD [3] Research Focus - The company utilizes proprietary technology to identify drug targets that can modulate gene expression to address the root causes of gene mis-expression [2]